According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical’s revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024.

What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, clickhere.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up forStock Watchtoday.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

COMTEX_465183536/2549/2025-05-03T16:06:58